Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage, potentially
Two medicine companies joined together to become one bigger company called Slate Medicines. They want to focus on making new medicines for migraines, which are really bad headaches that lots of people get.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.